401
Participants
Start Date
November 30, 2002
Primary Completion Date
April 30, 2004
Study Completion Date
April 30, 2004
Avelox (Moxifloxacin, BAY12-8039)
Moxifloxacin 400 mg IV QD for a minimum of two doses followed by moxifloxacin 400 mg PO QD for a total treatment duration of 7 to 14 days
Levofloxacin
Levofloxacin 500 mg IV QD for a minimum of two doses followed by Levofloxacin 500 mg PO QD for a total treatment duration of 7 to 14 days. For patients who have a documented or calculated creatinine clearance of 20 - 49 ml/minute, the IV and PO dose of Levofloxacin will be a 500 mg loading dose followed by 250 mg QD for a total treatment duration of 7 to 14 days
New York
Mineola
Kingston
Johnson City
Beaver
Allentown
Philadelphia
Cumberland
Norfolk
Winston-Salem
Winston-Salem
Elizabeth City
Summerville
Marietta
Blue Ridge
Fort Gordon
Columbus
Jacksonville
Brandon
Sarasota
Knoxville
Memphis
Lexington
Akron
Dayton
Lima
Indianapolis
Elk Grove Village
Springfield
Columbia
Omaha
New Orleans
New Orleans
San Antonio
Salt Lake City
Tucson
Tucson
La Jolla
Madera
Honolulu
Mobile
Brea
Fullerton
Bridgeport
Farmington
Stamford
Orlando
Tampa
Austell
Coeur d'Alene
Fort Wayne
Indianapolis
New Orleans
Shreveport
Kalamazoo
Royal Oak
Duluth
St Louis
Anaconda
Holmdel
Neptune City
Newark
Albany
Manhasset
New York
Syracuse
Chapel Hill
Columbus
Tulsa
Hershey
Jackson
El Paso
San Antonio
San Antonio
San Antonio
Lynchburg
San Juan
Lead Sponsor
Bayer
INDUSTRY